摘要
乙型肝炎病毒(Hepatitis B Virus, HBV)感染仍然是全球重要的公共卫生问题之一。近年来,随着抗病毒药物及治疗策略的不断优化,部分慢性HBV感染患者基于聚乙二醇干扰素(Pegylated Interferon, Peg-IFN)抗病毒疗效良好,部分患者甚至可获得临床治愈(乙型肝炎表面抗原(Hepatitis B surface Antigen, HBsAg)阴性伴或不伴乙型肝炎表面抗体(Hepatitis B surface Antibody, HBsAb)出现、HBV DNA检测不到、肝脏生物化学指标正常)且持久性好,慢性HBV感染相关不良事件风险显著降低,显著改善了慢性HBV感染者的远期预后。另外,随着慢性HBV感染临床分期诊断条件不断明确、完善、优化及慢性HBV感染人群的诊治需求变化,越来越多的慢性HBV感染者追求临床治愈,进而改善远期预后。因此,本文拟从最新慢性HBV感染者临床分期角度阐述慢性HBV感染者基于Peg-IFN治疗研究现状。
Hepatitis B virus (HBV) infection remains one of the most important public health problems worldwide. In recent years, with the continuous optimization of antiviral drugs and treatment strategies, some patients with chronic HBV infection have good antiviral efficacy based on Pegylated Interferon (Peg-IFN). Some patients may even be clinically cured (hepatitis B surface antigen (HBsAg) negative with or without hepatitis B surface antibody, HBsAb, HBV DNA is undetectable and liver biochemical markers are normal and HBsAg seroclearance was durable. The risk of adverse events related to chronic HBV infection is significantly reduced, and the long-term prognosis of chronic HBV infection is improved. In addition, with the continuous clarification, improvement and optimization of clinical staging diagnosis conditions of chronic HBV infection and the change of diagnosis and treatment needs of chronic HBV infected people, more and more chronic HBV infected people pursue clinical cure, so as to improve long-term prognosis. Therefore, this paper intends to discuss the current research status of Peg-IFN therapy based on the clinical staging of the latest chronic HBV infection.
出处
《临床医学进展》
2024年第3期1605-1611,共7页
Advances in Clinical Medicine
